In 2004, the Securities and Exchange Commission and the Food and Drug Administration announced steps to enhance cooperation between them to further protect the public from false and misleading statements by public life sciences companies. The agencies developed a centralized process where the FDA could refer potential disclosure matters to the SEC’s Division of Enforcement, and identify FDA point persons and procedures for the SEC to use when gathering information about public life-sciences companies. Reprinted with permission from Portfolio Media, Inc.
Related Insights
April 3, 2026
Energy Current
Texas Legislature Sets Its Sights on Data Centers and AI: What You Need to Know
Texas House and Senate leadership recently released their interim charges, which serve as "homework assignments" for legislative…
April 3, 2026
Foley Viewpoints
For Your Eyes Only? Not Quite: Shadow AI in the Workplace
While many companies are still developing governance frameworks for authorized AI tools, an emerging risk has quietly surfaced: employees using unauthorized transcription tools without the company’s or participants’ consent.
April 3, 2026
Manufacturing Industry Advisor
Connecticut Appellate Court Narrows Scope of Petroleum “Franchise” Protections for Gas Station Operators
The Appellate Court of Connecticut affirmed a trial court’s judgment in favor of a petroleum distributor/lessor, holding that convenience…